Partner with your clients
Decide on a long-term management plan that includes the Zoetis Dermatology Portfolio

Setting expectations and preparing for pruritic flares can protect clients' trust in their veterinarian

Allergic dermatitis requires lifelong management – even when controlled, occasional flares can occur¹
• Pruritic flares are to be expected, especially for seasonally affected dogs
Prepare your clients for the possibility of flares by establishing an individualized plan
Reassure your clients that their dog's current anti-pruritic treatment is still working
Apoquel (oclacitnib tablet) and Cytopoint can be used to relieve itch while completing a diagnostic workup, while CoNvenia (cefovecin tablet) treats bacterial skin infection. Simparica (sarolaner) is a monthly chewable that starts killing fleas fast, within 3 hours, to help keep dogs protected

–

Guidance for Successful Flare Management

Prepare for the possibility of a flare by maintaining open, two-way communication with the pet owner
If you suspect a flare, schedule an exam for the dog to be seen
Do not stop using the dogs current anti-pruritic treatment during the flare
Complete the diagnostic workup so the underlying cause of the flare (eg fleas, dietary indiscretion, infection) can be identified
Treat the flare with the appropriate therapy

Navigating flare management with your clients

Dixon's story: Managing a flare of allergic disease²

59 lb Labrador Retriever mix
Dixon presented with severe pruritis and was diagnosed with allergic dermatitis with secondary bacterial pyoderma
He was treated with Cytopoint to provide consistent itch relief that does not rely on his owner's ability to administer daily medication
A flea allergy flare caused lesions on Dixon's skin. Simparica was used to treat the fleas, while the lesions were treated woth Convenia another injectable ensuring 100% compliance
Within 24 hours Dixon's itch was significantly reduced. At the one-week recheck, his allergic dermatitis and bacterial infection had resolved

Exeland before CYTOPOINT for his atopic dermatitis

Presentation

Exeland after CYTOPOINT for his atopic dermatitis

After treatment

Relief for both pet and owner

"We have tried so many different things to alleviate his problems... by far, the CYTOPOINT and CONVENIA treatment has been the best response he's ever had."
- Megan, Dixon's owner

Next, Resources for your practice

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.
For more information, please see the full Prescribing Information.

CYTOPOINT Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

CONVENIA Indications: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis.

CONVENIA IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy.
For more information, please see the full Prescribing Information.

SIMPARICA Indications: SIMPARICA kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), lxodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs 6 months of age or older and weighing 2.8 pounds or greater.

SIMPARICA IMPORTANT SAFETY INFORMATION: Simparica is for use only in dogs, 6 months of age and older. Simparica may cause abnormal neurologic signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures. Simparica has not been evaluated in dogs that are pregnant, breeding or lactating. Simparica has been safely used in dogs treated with commonly prescribed vaccines, parasiticides and other medications. The most frequently reported adverse reactions were vomiting and diarrhea.
For more information, please see the full Prescribing Information.

References: 1. Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210. doi:10.1186/s12917-015-0514-6. 2. Data on file, Pet Owner Case Studies-Dixon, 2018, Zoetis Inc.

Testimonials represent individual experience only and the experiences and opinions herein may be unique to the patient and the speaker. Individual results may vary, considering the unique characteristics of the patient.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.